Targeted therapies, particularly immune-based approaches like chimeric antigen receptor (CAR)-modified T cells, are becoming integral to cancer treatments. While CAR-based cell therapies have shown success, challenges remain with solid tumors, prompting exploration of alternative cell types and targets. Cervical cancer poses a serious health risk for women worldwide, and with limited treatment options for recurrent or metastatic cases, it presents an opportunity for the development of new therapies.. Mesothelin, highly expressed in cervical and other cancers but minimally in healthy tissues, is a promising target. Although anti-Mesothelin CAR-T cells have demonstrated efficacy in other cancers, their potential in cervical cancer remains largely unexplored.

Spheroid formation:
Cell: SiHa cell line,Cell density: 1000 cells/well
Meduim: complete RPMI medium
Seeding and culture condition: PrimeSurfaceTM 96U plates were centrifuged at 125 xg for 10 min and incubated for 3-5 days in a humidified incubator at 37°C with 5% CO₂.
Spheroids were applied in 3D cytotoxicity assays: NK cells were added to the formed spheroids and co-culture for up tp 4 days
Cell viability was presented by fluorescent intensity

* For details, please refer to the paper